Speaking to the clinical significance of Lp(a) cascade screening, relatives with elevated Lp(a) and no familial hypercholesterolemia were at significantly elevated risk of reaching a composite endpoint of ASCVD (defined as any coronary, cerebrovascular, or peripheral arterial obstructive disease or revascularization) and cardiovascular mortality compared with relatives with normal Lp(a) and no familial hypercholesterolemia during a median follow-up time of 4.4 years after screening (hazard ratio: 3.17; 95% CI: 1.16–8.64; P = 0.024). The gene discussed is LPA; the disease is familial hypercholesterolemia.